Loading stock data…
SPRO
$2.48-0.03 (-1.20%)
After Hours$2.52+0.04 (+1.61%)· Last close May 1
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Spero Therapeutics, Inc. in the Healthcare sector is trading at $2.50. The stock is currently 22% below its 52-week high of $3.22, remaining 8.4% above its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why SPRO maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 33) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.48
Potential Downside
187.6%
Whystock Fair Value$-2.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$165.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.07
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-173.54%
Volume
Today's trading volume
453,410
Recent News
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said Axel-Sven Malkomes joined the company as Chief Financial Officer, while Susan Coles and Pamela Herbster started their roles as Chief Legal Officer and Chief People Officer, respectively. The additions come as Inventiva prepares for potential commercialization from the Phase 3 trial of its MASH therapeutic, expected in […]
Uncovering 3 Penny Stocks With Market Caps Under $700M
The market has climbed 1.2% in the last 7 days and is up 33% over the last 12 months, with earnings forecast to grow by 16% annually. Investing in penny stocks can still open doors to growth opportunities, typically in smaller or newer companies that come backed by strong financial health. Let's explore several penny stocks that could pair balance sheet strength with long-term potential.
Airgain And 2 Other Promising Penny Stocks
As February begins, the U.S. stock market has shown a robust start with major indexes like the Dow Jones Industrial Average and S&P 500 ending sharply higher. For those looking to invest in smaller or newer companies, penny stocks—despite their name's vintage feel—can still offer surprising value. This article explores three penny stocks that demonstrate financial strength and potential for long-term growth, offering an intriguing opportunity for investors seeking to diversify their...
3 Promising Penny Stocks With Market Caps Up To $300M
Major stock indexes in the United States have recently shown mixed performance, with the Dow Jones Industrial Average and S&P 500 setting fresh all-time highs. Amid these fluctuating market conditions, investors are increasingly exploring diverse opportunities to maximize potential returns. Penny stocks, though a term from earlier market days, continue to represent intriguing investment prospects by offering access to smaller or newer companies at lower price points. By identifying those with...
Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...